NEW YORK and CAESAREA, Israel, Sept.
23, 2019 /PRNewswire/ -- DarioHealth
Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a
leading, global digital therapeutics company, today announced that
Erez Raphael, DarioHealth's Chief
Executive Officer, will be a speaker at the second annual DTx East
2019 conference taking place at Harvard
Medical School in Boston,
MA from September 24-26,
2019.
DTx East provides a forum for key decision makers and innovators
in the rapidly expanding digital therapeutics industry to network,
learn and share ideas. The three-day conference provides a meeting
point for more than 300 senior leaders from a range of digital
therapeutic companies, including pharmaceutical companies,
investors, payers and health care providers.
Mr. Raphael will speak at the conference on September 26, 2019 on a panel titled "Digital
Therapeutics Deliver Evidence-based Results: The Example of
DarioHealth." In this panel, Mr. Raphael will discuss how increased
engagement through the use of digital therapeutics platforms and
empowerment of individuals managing chronic diseases leads to
highly beneficial health outcomes, when supported by the right
digital solutions and coaching.
"True innovation in any industry requires like-minded, visionary
and passionate people to come together and build a solution that
disrupts the industry. Our integrated digital approach to providing
health solutions to individuals with chronic conditions actively
empowers individuals to make the best, most-informed choices for
their own health - we believe this establishes a new paradigm in
Western medicine," said Mr. Raphael. "I look forward to sharing my
knowledge and best practices of how DarioHealth's digital
therapeutic solutions are changing the approach to chronic disease
care and will offer real-world, evidence-based examples of why our
approach works and will scale over time."
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading,
global digital therapeutics company revolutionizing the way
people with chronic conditions manage their health. By delivering
evidence-based interventions that are driven by data, high-quality
software and coaching, we empower individuals to make healthy
adjustments to their daily lifestyle choices to improve their
overall health. Our cross-functional team operates at the
intersection of life sciences, behavioral science and software
technology to deliver highly engaging therapeutic interventions.
Dario is one of the highest-rated diabetes solutions in the market,
and its user-centric MyDario™ mobile app is loved by
tens of thousands of consumers around the globe. DarioHealth is
rapidly moving into new chronic conditions and geographic markets,
using a performance-based approach to improve the health of users
managing chronic disease. To learn more about DarioHealth and its
digital health solutions, please go
to: http://mydario.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company discusses
Mr. Raphael's attendance at DTx East 2019 and the belief that
Dario's integrated digital approach to providing health solutions
to individuals with chronic conditions establishes a new paradigm
in Western medicine, it is using forward-looking statements.
Readers are cautioned that certain important factors may affect the
Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for Dario)
may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact:
Claudia
Levi
Content & Communications Manager
claudia@mydario.com
+1-347-767-4220
Media Inquiries:
Catherine
Polisi Jones
Polisi Jones Communications
cjones@polisijones.com
+1-917-330-8934
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dariohealth-ceo-erez-raphael-presents-to-digital-therapeutics-leaders-at-dtx-east-2019-300923065.html
SOURCE DarioHealth Corp.